Brexit Finally Here But Uncertainty Not Over For Biopharma
Doubts Persist On Regulatory Alignment And Migration
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
You may also be interested in...
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.